Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Serina Therapeutics, Inc. (SER)

Serina Therapeutics Says SER-252 Cohort 1 Advances Study to Cohort 2 Dose Escalation

Neutral Impact 3 of 5 other Written later

Serina Therapeutics reported that an independent Safety Monitoring Committee completed a blinded review of Cohort 1 in its Phase 1b study of SER-252 in advanced Parkinson's disease and recommended advancing to Cohort 2. Blinded Cohort 1 data at the lowest dose showed a pharmacokinetic profile consistent with sustained apomorphine exposure and sustained motor improvement in some individual patients on exploratory measures. The company expects topline data from the single-ascending-dose portion in the first half of 2027, but the Cohort 1 data are preliminary, blinded, exploratory and based on a small number of patients.

Key points

  • Cohort 1 enrolled eight patients, randomized 3:1 to SER-252 or placebo, and evaluated the lowest dose level.
  • The Independent Safety Monitoring Committee recommended advancing to Cohort 2 based on blinded safety and tolerability data.
  • Serina expects to report topline data from the single-ascending-dose portion of the study in the first half of 2027.
  • The filing states Cohort 1 data are preliminary, blinded, and exploratory and may not be evidence of treatment effect.

The filing

CompanySerina Therapeutics, Inc. (SER)
Form8-K, current report
Filed with the SECSep 9, 2026, 7:43 AM ET
Accession number0001708599-26-000054

Items reported: 8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 09, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.